Investors

News & Events

Selective Potentiation of NaV1.1 Channels by Small-Molecule XPC-837 in Dravet Mice Suppresses Spontaneous Seizures, Prevents SUDEP, Increases Long-Term Potentiation, and Normalizes Gene Expression

Tags
Early-Stage Programs

Congress: European Epilepsy Congress (September 6, 2026)
Authors: Goodchild SJ, et al.
Encore of AAN 2026

Investor inquiries

Tucker Kelly 
Chief Financial Officer
investors@xenon-pharma.com
 

Email alerts

Sign up here to receive email alerts from Xenon Pharmaceuticals